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Abstract
Background: Pruritic skin rashes associated with exposure to freshwater cyanobacteria are
infrequently reported in the medical and scientific literature, mostly as anecdotal and case reports.
Diagnostic dermatological investigations in humans are also infrequently described. We sought to
conduct a pilot volunteer study to explore the potential for cyanobacteria to elicit hypersensitivity
reactions.
Methods: A consecutive series of adult patients presenting for diagnostic skin patch testing at a
hospital outpatient clinic were invited to participate. A convenience sample of volunteers matched
for age and sex was also enrolled. Patches containing aqueous suspensions of various cyanobacteria
at three concentrations were applied for 48 hours; dermatological assessment was made 48 hours
and 96 hours after application.
Results:  20 outpatients and 19 reference subjects were recruited into the study. A single
outpatient produced unequivocal reactions to several cyanobacteria suspensions; this subject was
also the only one of the outpatient group with a diagnosis of atopic dermatitis. No subjects in the
reference group developed clinically detectable skin reactions to cyanobacteria.
Conclusion:  This preliminary clinical study demonstrates that hypersensitivity reactions to
cyanobacteria appear to be infrequent in both the general and dermatological outpatient
populations. As cyanobacteria are widely distributed in aquatic environments, a better appreciation
of risk factors, particularly with respect to allergic predisposition, may help to refine health advice
given to people engaging in recreational activities where nuisance cyanobacteria are a problem.
Background
Cyanobacteria, commonly but erroneously known as
blue-green algae, are common inhabitants of freshwater
lakes and reservoirs throughout the world. Under favour-
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able conditions certain cyanobacteria can dominate the
phytoplankton within a waterbody and undergo mass
developments, known as blooms. Public health concerns
arise because many nuisance cyanobacteria can produce
potent toxins. Anecdotal and case reports have docu-
mented skin rashes, often described as intensely pruritic,
associated with contact exposure to cyanobacteria. While
there are relatively few references in the scientific and
medical literature since these reports began in 1949,
under-diagnosis of cyanobacteria-associated illness was
suggested by Schwimmer & Schwimmer [1] in 1968, a sus-
picion that probably holds today. Most reports of cyano-
bacteria-associated skin eruptions describe recreational or
occupational exposure [2], however there are anecdotal
reports of skin rashes related to water treatment failures
and subsequent presence of cyanobacterial products in
reticulated supplies. In these instances, skin rashes were
reported after showering or bathing [3,4]. "Several" peo-
ple experienced acute dermatitis, as well as gastrointesti-
nal symptoms, after drinking water from a riverine source
affected by a cyanobacteria bloom in Portugal [5].
Skin patch testing is a routine diagnostic procedure in der-
matology clinics worldwide, and testing with cyanobacte-
rial preparations was first reported in the USA in 1953 to
investigate a water contact-related seasonal dermatitis in a
girl aged six years. Strong positive reactions to various
extracts of an Anabaena sp. dominant bloom sample were
observed on the child but none of 25 healthy control sub-
jects [6].
In a study of volunteers to investigate irritant reactions,
Pilotto et al [7] reported that 20–24% of subjects reacted
to cyanobacterial test patches, and 23% of subjects
responded to negative control patches. After excluding
subjects who responded to the negative controls, 11–15%
of subjects responded to cyanobacteria. No dose-response
relationships were reported.
Anecdotal and case reports in the medical and scientific
literature do not provide convincing descriptions of mass
outbreaks of cutaneous symptoms associated with recrea-
tional or occupational exposure to planktonic cyanobac-
teria. Rather, the picture is of isolated events affecting
individuals or small numbers of people [2]. An epidemi-
ological study to investigate the occurrence of acute symp-
toms did not find a statistically significant difference in
the reporting of cutaneous symptoms across groups
exposed to different levels of planktonic cyanobacteria in
recreational waters. The small number of subjects that
reported skin ailments after bathing in cyanobacteria-
affected waters mostly rated the severity of symptoms as
mild [8]. Taken together, these findings suggest that nui-
sance planktonic cyanobacteria are not commonly
present at irritant concentrations in inland recreational
waters, unlike the marine filamentous cyanobacterium
Lyngbya majuscula, which is known to produce dermally-
active toxins and has been linked to mass outbreaks of
acute dermatitis involving hundreds of individuals, with
high proportions of exposed individuals being affected
[9].
The purpose of this study was to assess the propensity for
a range of cyanobacterial suspensions to induce cutane-
ous irritant and hypersensitivity reactions in dermatology
outpatients and a reference group of volunteers matched
for age and sex. We wished to determine whether thresh-
old doses that induce reactions in the reference group, if
indeed such reactions occur in this group, are lower in
individuals with an active history of cutaneous symptoms.
Irritant and hypersensitivity reactions would be deter-
mined both qualitatively and quantitatively, and the
cyanobacteria would be characterised in terms of species
(or genera if speciation were not possible), doses to be
applied to the skin, and the presence or absence of known
toxins.
Methods
Study participants, patch application and reading
A consecutive series of adults aged 18 to 65 years present-
ing for diagnostic skin patch testing at the Royal Brisbane
and Women's Hospital dermatology outpatient clinic
between March 2002 and November 2003 was invited to
participate in the study – provided they met study inclu-
sion criteria – until 20 were recruited. A convenience sam-
ple of volunteers was recruited via notices posted at three
university sites and by word of mouth for the reference
group. Patients and reference subjects were matched by
sex and, where possible, by age using 5 year age bands.
Routine exclusion criteria for elective patch testing
applied to this study: persons with infectious dermatoses,
widespread acne, traumatic lesion or excess hair on their
back. Pregnant women were also excluded.
Study subjects were asked to complete a simple question-
naire that requested basic demographic details (age, sex),
history of allergic illness (asthma, hay fever, eczema, urti-
caria), relevant medications and a description of any
freshwater-related dermatoses [[10] (Appendix 4)].
The skin patch testing procedure uses a series of shallow
aluminium chambers (Finn chambers), 8 mm internal
diameter, 0.5 mm depth, into which test materials are
placed, either impregnated onto discs of filter paper or
mixed in petrolatum [11]. Test material is placed in each
chamber, and the Finn chamber strips are fixed on the
skin with non occlusive, non-allergenic and non-irritant
adhesive tape. For this study a clinic nurse prepared the
skin of each subject's back with acetone, and patches were
applied to the skin. Study subjects were instructed to keepBMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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their back dry, i.e. bathe but not shower, and to refrain
from sport or vigorous activity that might lead to frank
perspiration, with resultant separation of Finn chamber
strips from the skin. Patches were then removed after 48
hours. The clinic nurse marked the position of each Finn
chamber with a permanent marker pen; after allowing
adhesive tape-related erythema to subside, patch test sites
were read by a dermatologist after 48 and approximately
96 hours. Patch sites were scored according to the key in
Table 1.
Dermatology clinic workers were blinded to the identity
of test materials (patch series columns) but not to test
concentrations (patch series rows) because we thought
that identification of concentration-dependent (i.e. dose-
response) reactions to any particular test suspension series
would assist in the differentiation of irritant and hyper-
sensitivity responses. Clinic workers were not blinded to
the status of study subjects as either patients or non-
patients.
Ethical approvals for this study and amendments were
granted by the Royal Brisbane Hospital Health Service
District's Human Research Ethics Committee, protocol
number 2001/151, and the University of Queensland's
Medical Research Ethics Committee, clearance number
2002000099.
Patch test materials
Six cyanobacterial suspensions, two cyanobacterial
lipopolysaccharide extracts and one eukaryotic algal sus-
pension were tested, each at three concentrations. Sodium
dodecyl sulfate was used as a positive irritant control. The
test materials and measured cyanotoxin concentrations
are listed in Table 2.
Culturing of cyanobacterial isolates; preparation of stock 
suspensions
Cyanobacteria isolates were non-axenic laboratory cul-
tures grown in sterile inorganic media in an illuminated
growth chamber at 28°C with a 14:10 light/dark cycle.
Culture vessels were aerated with aquarium pumps and
Table 1: Patch testing interpretation key
+/- Uncertain reaction: faint macular erythema only
+ Weak (nonvesicular) positive reaction; erythema, infiltration, 
possibly papules
++ Strong (vesicular) positive reaction; erythema, infiltration, 
papules, vesicles
+++ Extreme positive reaction; bullous reaction
- Negative reaction
IR Irritant reaction of different types
Adapted from Rietschel & Fowler [16 (p. 24)] (interpretation key of 
the International Contact Dermatitis Research Group).
Table 2: Suspensions and extracts applied to patch test wells
Test material or species Patch series type Strain Source Cyanotoxin (concentration in 
0.25% w/v lyophilised cyanobacteria 
patch preparation)
Sodium dodecyl sulfate 
(SDS, aka sodium lauryl 
sulfate)
Positive irritant 
control
Sigma-Aldrich P/L
Cylindrospermopsis raciborskii Cyanobacterial cell 
suspension
AWT 205 
Non-axenic
Australian Water Technologies 
culture collection Sydney, 
Australia
Cylindrospermopsin (2.0 mg/L)
C. raciborskii Cyanobacterial LPS 
extract
AWT 205 
Non-axenic
Australian Water Technologies 
culture collection Sydney, 
Australia
Microcystis aeruginosa 
C. raciborskii 
Aphanizomenon sp.
Cyanobacterial cell 
suspension
Field sample, North Pine Dam 
(South-east Queensland, 
Australia)
Microcystins (200 µg/L total 
microcystins expressed as MC-LR); 
cylindrospermopsin (6.4 µg/L)
M. aeruginosa Cyanobacterial cell 
suspension
Field sample, Lake Coolmunda 
(Southern Queensland, Australia)
Non-toxic (nil detect for microcystins)
M. aeruginosa Cyanobacterial LPS 
extract
Field sample, Lake Coolmunda 
(Southern Queensland, Australia)
M. aeruginosa Cyanobacterial cell 
suspension
QH/NR/Ma/03 
Non-axenic
Queensland Health Scientific 
Services culture collection, 
Brisbane, Australia
Microcystins [predominantly 
microcystin-LR] (1.60 mg/L total 
microcystins expressed as MC-LR)
Anabaena circinalis Cyanobacterial cell 
suspension
Field sample, Lake Coolmunda 
(Southern Queensland, Australia)
Saxitoxins (19 µg/L total saxitoxins 
expressed as saxitoxin)
Planktothrix sp. Cyanobacterial cell 
suspension
QH/NR/Px/01 
Non-axenic
Queensland Health Scientific 
Services culture collection, 
Brisbane, Australia
Non-toxic (nil detect for microcystins)
Chlorella vulgaris Green algal cell 
suspension
CS-42 Non-
axenic
CSIRO collection of living 
microalgae, Hobart, AustraliaBMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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air-stones connected by PVC tubing; air was delivered
through 0.45 µm Millipore® filters, and all culture vessels
and air delivery components distal to the filter (tubing,
weights and air-stones) were sterilised prior to use by
steam autoclaving or Sterrad® hydrogen peroxide plasma
sterilisation (the latter for heat labile plastics).
M. aeruginosa and Planktothrix sp. cultures were grown in
20L batch cultures; M. aeruginosa cells were harvested by
placing the culture vessel in a darkened cupboard over-
night. This caused cells to rise to the surface of the vessel
where they were aspirated with a syringe and PVC tubing.
Planktothrix sp. is a filamentous cyanobacterium, so was
easily harvested by plucking it in several continuous
sheets from the vessel walls and aeration tubing. C. raci-
borskii was produced by continuous culture adapted from
the method of Court et al [12] and cells were concentrated
by centrifugation in 750 mL centrifuge bottles, then
decanting and discarding media. Cells were double-
washed by repeat suspension in de-ionised water followed
by centrifugation. 250 mL of C. vulgaris culture was pur-
chased from CSIRO Hobart, which after double washing
yielded sufficient cellular material for this work. Har-
vested cells were lyophilised, powdered with a domestic
coffee grinder and stored at room temperature in air-tight
containers.
Stock preparations were made by suspending 25 mg
lyophilised cells in 10 mL Milli-Q® filtered water to pro-
duce 0.25% w/v suspensions. These were steeped over-
night at 4°C. Cell integrity was disrupted by subjecting
each suspension to ultrasonic pulsing for 30 seconds,
using a Branson Ultrasonics Sonifier 450 instrument.
From each 0.25% preparation 1 mL was added to 4 mL
Milli-Q® water to produce the 0.05% suspension, and 0.5
mL of that preparation was added to 4.5 mL water for the
0.005% suspension. All suspensions were stored at -20°C.
Lipopolysaccharide (LPS) solutions were prepared from
LPS isolated and purified with a hot phenol method and
ultracentrifugation, per procedures No. 4: Bacterial
lipopolysaccharides – Gram-negative (modified West-
phal) and No. 27: Purification of lipopolysaccharide
(modified Westphal) ([13], (pp.3-4, 31-2)), from the
process described by Westphal & Jann [14]. LPS concen-
trations were based on the percentage yield from cyano-
bacterial whole cells they were extracted from:
• M. aeruginosa LPS was 0.51% of dry cell weight, so the
maximum concentration of LPS for skin patch testing was
(5.1 × 10-3) × 0.25% w/v, i.e. 13 ppm. Intermediate and
low concentrations were prepared by diluting the 13 ppm
concentration as described above to give 3 ppm and 300
ppb concentrations.
• C. raciborskii LPS was 1.25% of dry cell weight, so the
three concentrations of this LPS were 30 ppm, 6 ppm and
600 ppb.
Sodium dodecyl sulfate was prepared at concentrations of
2.0%, 0.4% and 0.04% (w/v in Milli-Q® water) and stored
at -20°C.
Microcystins, saxitoxins and cylindrospermopsin were
quantified at Queensland Health Scientific Services, Bris-
bane. These data are included in Table 2; methodology
and instrumentation were as outlined in the accompany-
ing paper by Stewart et al [15].
Calculation of cyanotoxin doses applied to skin
Cyanobacterial cell suspensions were applied to filter
paper discs that fit into each Finn chamber. A plastic trans-
fer pipette was used to saturate each disc; one or two drops
– mostly one drop – are sufficient to saturate the disc. The
volume of two transfer pipette drops was measured with
an air displacement pipette and found to be 65 µL. Doses
were calculated from the maximum concentration (0.25%
w/v), then one fifth and one fiftieth of the maximum
dose, representing the 0.05% w/v and 0.005% w/v con-
centrations, were added to estimate the total cutaneous
dose for an average 65 kg subject.
Statistical analysis
Comparisons of categorical variables were undertaken
using Fisher's exact test. A p-value < 0.05 was used to
define statistical significance and all calculations were
conducted using SPSS v13.0. Investigation into the inci-
dence of reactions and threshold concentrations of cyano-
bacteria, adjusted for covariates including reported
history of asthma, urticaria or hay fever was planned but
not done because only a single subject developed une-
quivocal reactions to patches containing cyanobacteria.
Results
From the consecutive series of outpatients approached,
two declined to participate (one of each sex) and one
female who agreed to participate was not included due to
an administrative oversight. All outpatients were matched
to reference subjects by sex (females: n = 12; males: n = 8).
Matching was also done by age (± 5 years), except for three
older outpatient subjects (aged 54, 56 and 62 years).
Responses to the questionnaire enquiry regarding a previ-
ous history of allergic illness and acute or chronic skin
reactions are summarised in Table 3. Outpatients reported
significantly more life-time and recent eczema or dermati-
tis diagnoses (p = 0.04 and p = 0.01 respectively), and rash
of unknown cause within the last two years (p = 0.003)
than their reference counterparts.BMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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Skin patch testing – cyanobacterial and algal suspensions
Subjects CO10 and PT05 were removed from considera-
tion of summary statistics given in Table 2. Subject CO10
developed a localised folliculitis over four test series sites
– one being the SDS series – so 96-hour readings were
uninterpretable. The dermatologist noted a general irri-
tant reaction over the patch area. We were unable to
recruit another volunteer in her place, thus the study
included 19 reference subjects. Subject PT05 developed
"angry back", which is a state of skin hyper-reactivity
caused by a strong reaction to one or more patch-test aller-
gens, and is associated with false-positive reactions to
other test materials [[16] (pp. 16–17)]; another outpa-
tient subject was recruited to replace this subject in the
study.
Table 4 shows results of patch test inspections of the
cyanobacterial and algal series. Only one of the outpatient
group and none of the reference group showed an une-
quivocal reaction to cyanobacterial preparations. A weak
irritant response to an A. circinalis patch was seen in
another dermatology outpatient subject, and equivocal
responses to various patch materials were seen in four
patients and four reference subjects.
Estimated cyanotoxin doses applied to each subject are
presented in Table 5. Assuming that two drops of cell sus-
pension were required to saturate each Finn chamber filter
disc, and also assuming that the entire volume applied to
the discs was in contact with subjects' skin, all doses were
well below the mammalian i.p. toxic dose.
Discussion
Patch-testing of cyanobacteria and C. vulgaris
Only one clear response to this skin-patch testing study
was seen, from PT19, a male outpatient subject aged 35
years. Interestingly, this subject was also the only one of
20 outpatients with a diagnosis of atopic dermatitis. We
did not conduct any statistical analysis of these results, as
it is not appropriate to make such comparisons on the
basis of a single subject response. This subject developed
unequivocal responses to two cyanobacterial isolates, two
bloom samples, and probably to C. vulgaris as well. There
was no evidence of any dose-response effect in the reac-
Table 5: Estimated doses of cyanotoxins by the cutaneous route
Cyanotoxin Dose per subject Dose by weight* Mouse LD50(i.p.)
Cylindrospermopsin 160 ng 2.4 ng/kg 2.1 mg/kg (24 hours); 200 µg/kg (5–6 days) [31]
Microcystins 170 ng 2.6 ng/kg 45–70 µg/kg (most toxic forms) [32 (p. 140)]
Saxitoxins 3.8 ng 58 pg/kg 10–30 µg/kg [32 (p. 140)]
*Dose by weight estimated for a 65 kg individual
Table 3: Summary of questionnaire responses: history of cutaneous and allergic illness. n (%)
Outpatients Reference subjects
Yes No Not sure Yes No Not sure p
Eczema or dermatitis
Ever diagnosed 12(60) 4(20) 1(5) 7(37) 12(63) 0 0.04
Last two years 11(55) 3(15) 3(15) 5(26) 13(68) 0 0.01
Asthma
Ever diagnosed 6(30) 13(65) 0 8(42) 10(53) 0 0.51
Last two years 5(25) 14(70) 0 5(26) 13(68) 0 1.0
Hay fever
Ever diagnosed 2(10) 15(75) 1(5) 5(26) 14(74) 0 0.41
Last two years 3(15) 14(70) 1(5) 4(21) 15(79) 0 1.0
Urticaria
Ever diagnosed 1(5) 17(85) 1(5) 2(11) 16(84) 0 1.0
Last two years 0 17(85) 1(5) 1(5) 16(84) 1(5) 1.0
Rash of unknown cause
Last two years 10(50) 4(20) 3(15) 3(16) 15(79) 0 0.003
Rash after freshwater recreation 1(5) 16(80) 1(5) 0 15(79) 3(16) 1.0
n = 20 for the outpatient subject group; n = 19 for the reference group. Where sum of row answers (yes/no/not sure) is below the total, shortfall 
represents unanswered questions.
p-values: Fisher's exact test comparing proportion of "yes" and "no" answers between outpatient and reference subject groupsBMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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tions on this subject's skin. Another point of interest in
this subject's patch-test results is that reactions developed
to the non-toxic Lake Coolmunda M. aeruginosa bloom
sample, but no reaction was produced by the toxin-pro-
ducing  M. aeruginosa isolate. While the Coolmunda
bloom sample was largely a monoculture of M. aeruginosa,
as with many cyanobacteria blooms there were other
cyanobacterial species and genera present in smaller
amounts. This leaves open the possibility that this subject
has demonstrated hypersensitivity reactions to compo-
nents other than M. aeruginosa in the two bloom samples.
Subject PT19 also registered positive responses to both
patch series containing C. raciborskii and cylindrosper-
mopsin (C. raciborskii AWT 205 isolate and North Pine
Dam bloom sample). This is interesting in light of the
findings by Stewart et al [15], which demonstrate that C.
raciborskii and purified cylindrospermopsin are capable of
producing irritant reactions and delayed-contact hyper-
sensitivity in mice.
The principal conclusions from this study are that cutane-
ous responses to cyanobacteria are uncommon, with only
one of 39 subjects demonstrating significant cutaneous
responses to cyanobacterial suspensions. Given this
patient's diagnosis of atopic dermatitis, and reports in the
literature which are suggestive of other features of atopy
[2], further research into this matter may benefit from
more specific entry criteria to allow investigation of atopic
individuals. This sole diagnosis of atopy must be inter-
preted cautiously, however, in that diagnoses were only
available for the twenty outpatients. As the reference
group did not have a comprehensive medical history
taken, we cannot infer presence or absence of atopic sub-
jects within the reference group.
Weak reactions to C. vulgaris were seen on the skin of sub-
ject PT19, and possibly one other subject (PT04). C. vul-
garis, a common and widespread eukaryotic alga, was
chosen as a reference material; Chlorella spp. are report-
Table 4: Cyanobacterial and algal patch series: positive and equivocal patch test results
Subject
Test material Concentration PT01 PTO2 PT04 PT06 PT19 CO05 CO06 CO08 CO09
C. raciborskii 0.005% (++)* (+)**
AWT 205 cell 0.05% (++)* (+)**
suspension 0.25% (++)* (+)**
C. raciborskii 630 ppb (+/-)*
AWT 205 LPS 6 ppm
extract 31 ppm
M. aeruginosa
C. raciborskii 0.005% (+)* (+)**
Aphanizomenon sp. 0.05% (++)* (+)**
North Pine Dam cell suspension 0.25% (+)* (+)**
M. aeruginosa 0.005% (+)**
Lake Coolmunda 0.05% (+)**
cell suspension 0.25% (+/-)* (+/-)**
M. aeruginosa 260 ppb (+/-)*
Lake Coolmunda 3 ppm (+/-)* (+/-)**
LPS extract 13 ppm (+/-)* (+/-)**
M. aeruginosa 0.005% (+/-)*
QH/NR/Ma/03 cell 0.05%
suspension 0.25% (+/-)* (+/-)*
A. circinalis 0.005%
Lake Coolmunda 0.05% (+/- IR)* (+/-)*
cell suspension 0.25% (+ IR)*
Planktothrix sp. 0.005%
QH/NR/Px/01 cell 0.05% (+)* (+)* (+)**
suspension 0.25% (+)**
C. vulgaris 0.005% (+/- IR)* (+/-)* (+)*
CS-42 cell 0.05% (+/-)* (+)* (+/-)*
suspension 0.25% (+/-)* (+)*
*: grading at 48-hour inspection
**: grading at 96-hour inspection
Subject prefix "PT" = dermatology outpatient subject
Subject prefix "CO" = non-patient volunteerBMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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edly allergenic [17,18], although C. vulgaris has been pro-
moted as an allergy preventative and has some anti-
inflammatory properties [19]. Acute skin symptoms have
been reported from exposure to other freshwater and
marine eukaryotic microalgae [20,21].
Considering the single subject response to cyanobacterial
patch testing, these data were used to determine sample
size estimates that would produce with high probability a
statistically significant result. Using nQuery Advisor® 4.0
[22], a Fisher's exact test with α = 0.05 two-sided signifi-
cance level will have 80% power to detect the difference
between a Group 1 proportion of 0.050 and a Group 2
proportion of 0.001 when the sample size in each group
is 167. A study involving over 300 volunteers would be
prohibitively large and expensive; a more targeted
approach in future to recruit subjects from more at-risk
populations awaits further knowledge of the mechanisms
of cyanobacterial toxicity by the cutaneous route.
History of skin disease, allergy
As anticipated, the outpatient group contained a higher
proportion of subjects with cutaneous disease than the
reference group (see Table 3). However, the percentage of
subjects reporting hay-fever, asthma and urticarial diag-
noses was higher in the reference group, although these
differences were not statistically significant. To the extent
that future research efforts in this field may need to con-
centrate on those individuals with atopic illness, recruit-
ment from a dermatology outpatient population may not
confer any particular advantage over recruitment from the
general population.
Reactions to sodium dodecyl sulfate
Overall, 44% of subjects (n = 17) did not respond to SDS.
Some workers have added SDS to their standard allergy
patch test series in order to help differentiate between irri-
tant and allergic reactions [23,24]. However, these work-
ers did not appear to have blinded themselves to the
location of SDS patches; they were apparently using reac-
tions to SDS as reference irritant responses from which to
compare reactions to allergen patches. We suspect that the
inclusion of SDS as a positive irritant control may not
have been the most appropriate procedure in this diag-
nostic patch testing study; this matter is discussed further
by Stewart [[10] (Chapter 4)].
Rationale for determining cyanobacteria concentrations in 
patch test wells
Our initial challenge was to determine appropriate doses
of cyanobacteria to apply to human skin. Prior to com-
mencing this human volunteer study, preliminary irritant
mouse ear swelling work had been done with two cyano-
bacterial suspensions: M. aeruginosa QH/NR/Ma03, 5%
w/v and A. circinalis non-toxic bloom sample, Gordon-
brook Dam, Queensland, 10% w/v (lyophilised cyano-
bacteria in 75% methanol), with negative results [15].
Rietschel & Fowler [[16] (p. 15)] nominate appropriate
steps for testing non-standard contactants: initial test con-
centrations of 0.1% to 1.0% performed on several volun-
teers, including the investigator. An autoexperiment was
conducted on author IS in May 2001. Eight Finn cham-
bers containing 5% w/v suspensions of M. aeruginosa QH/
NR/Ma03 and the Gordonbrook Dam bloom sample con-
taining predominantly A. circinalis were prepared; each
suspension was applied with three vehicles: Milli-Q®
water, 50% v/v methanol in Milli-Q® water, and acetone.
Lyophilised, powdered M. aeruginosa and A. circinalis cells
were each mixed in petrolatum and placed into two of the
Finn chambers. Mild irritant reactions were seen on the
aqueous A. circinalis suspension site, and on the two pet-
rolatum sites. Because author IS has never suffered from
dermatitis, we suspected that the irritant reaction, albeit
mild, was probably the result of an artificially high con-
centration of cyanobacterial cells. So the maximum con-
centrations of cyanobacteria applied to the skin of
volunteers (0.25% w/v) were 20-fold lower than the con-
centration that elicited a mild irritant reaction on the skin
of author IS during pre-testing experiments; 0.25% is also
20 to 40-fold lower than concentrations that failed to
elicit observable or measurable reactions on mouse ears
during open application experiments for irritancy [15].
We did not proceed with using powdered, lyophilised
cyanobacteria mixed in petrolatum because of the antici-
pated loss of precision in determining doses. It was
elected to use aqueous cyanobacterial suspensions for
these patch testing studies, as water is the solvent of choice
in the vast majority of recreational settings, from which
arise reports of acute cyanobacteria-related dermatoses.
Concomitant exposure to ethanol can often be observed
in Australian recreational environments, but not by the
cutaneous route.
General discussion
The findings of this small human study are that cutaneous
reactions to cyanobacteria are infrequent, at least in the
population we sampled and the dose ranges we used. The
work in the accompanying paper by Stewart et al [15]
complements this study, and demonstrates that purified
cylindrospermopsin is capable of eliciting irritant and
delayed-contact hypersensitivity reactions in mice. The
small number of case and anecdotal reports in the litera-
ture also shows that cyanobacteria-associated dermatoses
are infrequently reported, although mild, self-limiting ill-
nesses, including pruritic rashes, are likely to be under-
reported and under-diagnosed [[2,25] (p. 69)]. However,
anecdotal reports of incident-free exposures to high levels
of cyanobacteria have also been received [[10] (Chapter
4)]; author IS has tried without success to generate a cuta-
neous response on his own skin through open applicationBMC Dermatology 2006, 6:6 http://www.biomedcentral.com/1471-5945/6/6
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of concentrated cyanobacterial cells on many occasions,
from both field samples and laboratory isolates. Images of
field workers demonstrating similarly enthusiastic disre-
gard for occupational health and safety matters can be
seen at [26-28].
The commercial sector has not been slow to realise that
cutaneous responses to cyanobacteria are not unequivo-
cally hazardous. A Google search using the terms "blue
green algae" "soothes" and "skin" reveals a bewildering
array of products and services that promise relief from
much of what ails you. Many of these products are made
from Arthrospira sp., a cyanobacterium also known as spir-
ulina. Clinical and research dermatologists will no doubt
be pleased to hear about:
Spirulina wrap : Rich in antioxidant vitamins, spirulina is
the ultimate nutrient boost. This treatment stimulates and
nourishes the skin while promoting a healthy, more
vibrant appereance (sic). (50 minutes) [29]
So there is still a great deal to learn about cyanobacteria
and the skin. To what degree these widespread organisms
may affect the health of individuals with atopic and non-
atopic allergic disease is unknown, but deserves the atten-
tion of researchers. The subject of photoallergy and pho-
toirritancy has not been investigated. Most environmental
exposures to aquatic cyanobacteria occur in recreational
settings, which correlate strongly with exposure to sun-
light, so photic effects should presumably be investigated.
Whether cyanobacteria-associated cutaneous eruptions in
susceptible individuals are primarily irritant reactions,
immediate hypersensitivity or delayed contact hypersensi-
tivity responses is not at all clear. The picture may turn out
to be complex and varied, with similarities to the broad
topic of phytodermatitis. Wilkinson and Shaw [30] list the
principal presenting features of phytodermatitis thus:
1. irritant contact phytodermatitis – both chemical and
physical
2. allergic contact phytodermatitis – both immediate and
delayed
3. phytophototoxic dermatitis
4. pseudophytophotodermatitis...
5. allergic contact phytodermatitis with secondary photo-
sensitivity...
Cyanobacteria-related dermatoses may also operate
through different molecular mechanisms and may there-
fore vary in clinical presentation via: individual suscepti-
bility (e.g. atopic phenotype), cyanobacteria profile in
waterbodies (different species, genera, cell biomass), cya-
notoxins (different types, different mechanisms of toxic-
ity, and variable concentration in waterbodies – i.e.
exposure and dose concerns), disruption to barrier func-
tion from waterlogged skin, and the influence of ultra-vio-
let irradiation (phototoxic effects or
immunosuppressive?).
Conclusion
This pilot study of 39 volunteers identified a single indi-
vidual with atopic disease who responded to several
cyanobacterial preparations applied to the skin by closed
patch testing. Dose-response relationships were not
observed in this individual, which supports the clinical
findings that these were hypersensitivity reactions. This
subject developed positive responses to all patch sites con-
taining cylindrospermopsin, whereas none of the remain-
ing 38 subjects showed any response to
cylindrospermopsin. This work complements a mouse
model study of delayed-contact hypersensitivity that dem-
onstrates cylindrospermopsin is active in mammalian epi-
dermal tissues. Future work into cutaneous effects of
cyanobacteria in humans may benefit from improved
awareness of cellular and molecular mechanisms to allow
more refined targeting of higher-risk populations.
As case reports and epidemiologic studies do not present
convincing findings of mass outbreaks of acute cutaneous
responses to planktonic freshwater cyanobacteria, the
possibility that many such reports are due to hypersensi-
tivity reactions should be considered; these preliminary
studies would seem to support this concept.
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